---
title: "NKGen Biotech, Inc. (NKGN.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NKGN.US/overview.md"
symbol: "NKGN.US"
name: "NKGen Biotech, Inc."
parent: "https://longbridge.com/en/quote/NKGN.US.md"
datetime: "2026-04-05T03:04:25.861Z"
locales:
  - [en](https://longbridge.com/en/quote/NKGN.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NKGN.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NKGN.US/overview.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/NKGN.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/NKGN.US/overview.md)


# NKGen Biotech, Inc. (NKGN.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | 3001 Daimler Street, Santa Ana, California, United States |
| Website | [nkgenbiotech.com](https://nkgenbiotech.com) |

## Company Profile

NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. It has a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize the company’s autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan. The company also has a license agreement with NKMAX Co., Ltd.

## Key Executives

| Name | Title |
|------|-------|
| Paul Y. Song | CEO & Chairman |
| James A. Graf | Interim Chief Financial Officer |
| Yoonmi Kang | SVP of Technical Ops & Development |
| Yong Man Kim | Chief Scientific Officer |
| Irene Chang | SVP, HR & Corporate Culture |
| Michael L. Klowden | Independent Director |
| Kathleen D. Scott | Independent Director |
| Anthony T. Reder | Member of Scientific Advisory Board |
| Craig Blackstone | Member of Scientific Advisory Board |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| CFIC-2015 NV Family Investments, LLC | 16.66% | 2025-10-07 |
| Paul Y. Song | 16.10% | 2025-10-07 |
| NKMAX CO., Ltd. | 7.75% | 2025-10-07 |
| HekaBio K.K. | 6.13% | 2025-10-07 |
| Meteora Capital, LLC | 2.11% | 2025-12-31 |
| James A. Graf | 1.60% | 2025-10-07 |
| Peggy Tsiang Cherng | 1.60% | 2024-08-12 |
| Yong Man Kim | 0.02% | 2025-10-07 |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**